Matches in UGent Biblio for { <https://biblio.ugent.be/publication/830089#aggregation> ?p ?o. }
Showing items 1 to 44 of
44
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B190685.
- aggregation creator B190686.
- aggregation creator B190687.
- aggregation creator B190688.
- aggregation creator B190689.
- aggregation creator B190690.
- aggregation creator B190691.
- aggregation creator B190692.
- aggregation creator B190693.
- aggregation creator B190694.
- aggregation creator B190695.
- aggregation creator B190696.
- aggregation creator person.
- aggregation date "2009".
- aggregation format "application/pdf".
- aggregation hasFormat 830089.bibtex.
- aggregation hasFormat 830089.csv.
- aggregation hasFormat 830089.dc.
- aggregation hasFormat 830089.didl.
- aggregation hasFormat 830089.doc.
- aggregation hasFormat 830089.json.
- aggregation hasFormat 830089.mets.
- aggregation hasFormat 830089.mods.
- aggregation hasFormat 830089.rdf.
- aggregation hasFormat 830089.ris.
- aggregation hasFormat 830089.txt.
- aggregation hasFormat 830089.xls.
- aggregation hasFormat 830089.yaml.
- aggregation isPartOf urn:issn:0300-0664.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study".
- aggregation abstract "This prospective randomized study evaluated the efficacy and safety of octreotide LAR vs. surgery in newly diagnosed acromegalic patients. Totally 104 male and female patients were enrolled in a 50-week, exploratory, open-label and randomized study. Eligible patients were randomized to receive either octreotide LAR 20 mg every 28 days or to undergo surgery. Efficacy was assessed by changes in mean GH and IGF-I serum concentrations, at weeks 12, 24 and 48. Tumour volume was assessed by contrast-enhanced MRI. In both groups, treatment adjustment was performed for patients uncontrolled at week 12 or 24. Octreotide LAR patients received a dose increased to 30 mg or, if already receiving this dose, investigator and patients could decide to cross-over to surgery. Patients uncontrolled after surgery received octreotide LAR 20 mg, increased to 30 mg if acromegaly was still uncontrolled. Overall success rates at weeks 24 and 48 were 25% and 28% for the octreotide LAR group and 49% and 39% for the surgery group. Only the difference observed at week 24 was statistically significant (P = 0.047). Both groups had a significant (> 20%) tumour shrinkage: 73% of patients in the octreotide LAR group and 95% in the surgery group. Major differences between octreotide LAR and surgery group in the occurrence of adverse events were gastrointestinal (71% vs. 27%), hepatobiliary (41% vs. 8%) and respiratory (5% vs. 28%). This first randomized study in unselected patients indicates that the 48-week treatment outcome of octreotide LAR as first-line treatment of acromegaly does not significantly differ from surgery. As a complete response to surgery in GH-secreting macro-adenomas can be difficult, first-line therapy with octreotide LAR can be considered as a viable alternative for most patients with acromegaly, due to its low complication rate.".
- aggregation authorList BK449430.
- aggregation endPage "768".
- aggregation issue "5".
- aggregation startPage "757".
- aggregation volume "70".
- aggregation aggregates 835109.
- aggregation isDescribedBy 830089.
- aggregation similarTo j.1365-2265.2008.03441.x.
- aggregation similarTo LU-830089.